Pluripotent Stem Cells [PSCs] are emerging as an excellent cellular source for the treatment of many degenerative diseases such as diabetes, ischemic heart failure, Alzheimer’s disease, etc. PSCderived pancreatic islet β-cells appear to be a promising therapy for type 1 diabetic patients with impaired β-cell function. Several protocols have been developed to derive β-cells from PSCs. However, these protocols produce β-like cells that show low glucose stimulated insulin secretion (GSIS) function and mirror GSIS profile of functionally immature neonatal β-cells. Several studies have documented a positive correlation between the sirtuins (a family of ageing-related proteins) and the GSIS function of adult β-cells. We are of the view that the GSIS function of PSC-derived β-like cells could be enhanced by improving the function of sirtuins in them. Studying the sirtuin expression and activation pattern during the β-cell development and inclusion of the sirtuin activators and inhibitor cocktail (specific to a developmental stage) in the present protocols may help us derive functionally mature, ready-to-use β- cells in-vitro making them suitable for transplantation in type 1 diabetes.

多能干细胞 [PSC] 正在成为治疗许多退行性疾病（如糖尿病、缺血性心力衰竭、阿尔茨海默病等）的极好细胞来源。 PSC 衍生的胰岛 β 细胞似乎是 1 型糖尿病患者的一种有前途的疗法β 细胞功能受损。已经开发了几种协议来从 PSC 中提取 β 细胞。然而，这些协议产生的 β 样细胞显示出低葡萄糖刺激的胰岛素分泌 (GSIS) 功能，并反映了功能不成熟的新生儿 β 细胞的 GSIS 特征。几项研究已经证明，sirtuins（衰老相关蛋白家族）与成人 β 细胞的 GSIS 功能之间存在正相关。我们认为可以通过改善 PSC 衍生的 β 样细胞中的 Sirtuins 的功能来增强它们的 GSIS 功能。